Icahn Wins Two Seats On Biogen Idec’s Board
This article was originally published in The Pink Sheet Daily
Executive Summary
Icahn Partners’ Managing Director Alex Denner claims victory after a drama-packed day that took an unusual twist.
You may also be interested in...
Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule
In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.
Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule
In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.
Genzyme, Icahn Call Off Proxy Fight With Compromise Agreement
In exchange for withdrawing its proxy slate and agreeing to back Genzyme's nominees, Icahn Partners get two seats on biotech's board.